Psychiatric comorbidity in methamphetamine dependence
Abstract The primary aim of the present study was to assess the prevalence of psychiatric comorbidity in a large sample of methamphetamine (MA)-dependent subjects using a validated structured clinical interview, without limitation to sexual orientation or participation in a treatment program. The se...
Gespeichert in:
| Veröffentlicht in: | Psychiatry research 2011-04, Vol.186 (2), p.356-361 |
|---|---|
| Hauptverfasser: | , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 361 |
|---|---|
| container_issue | 2 |
| container_start_page | 356 |
| container_title | Psychiatry research |
| container_volume | 186 |
| creator | Salo, Ruth Flower, Keith Kielstein, Anousheh Leamon, Martin H Nordahl, Thomas E Galloway, Gantt P |
| description | Abstract The primary aim of the present study was to assess the prevalence of psychiatric comorbidity in a large sample of methamphetamine (MA)-dependent subjects using a validated structured clinical interview, without limitation to sexual orientation or participation in a treatment program. The secondary aim was to assess whether the prevalence of psychiatric comorbidities varied by gender. Structured clinical interviews (SCIDs) were administered to 189 MA-dependent subjects and lifetime prevalence of DSM-IV diagnoses was assessed. Across the sample, 28.6% had primary psychotic disorders, 23.8% of which were substance-induced; 13.2% had MA-induced delusional disorders and 11.1% had MA-induced hallucinations. A substantial number of lifetime mood disorders were identified that were not substance-induced (32.3%), whereas 14.8% had mood disorders induced by substances, and 10.6% had mood disorders induced by amphetamines. Of all participants, 26.5% had anxiety disorders and 3.7% had a substance-induced anxiety disorder, all of which were induced by MA. Male subjects reported a higher percentage of MA-induced delusions compared to female abusers. Given the impact of MA psychosis and other drug-induced symptoms on hospitals and mental health services, the description and characterization of comorbid psychiatric symptoms associated with MA use is of paramount importance. |
| doi_str_mv | 10.1016/j.psychres.2010.09.014 |
| format | Article |
| fullrecord | <record><control><sourceid>elsevier_pubme</sourceid><recordid>TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_3058719</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><els_id>1_s2_0_S0165178110005913</els_id><sourcerecordid>1_s2_0_S0165178110005913</sourcerecordid><originalsourceid>FETCH-LOGICAL-c555t-d23ee1e007554de2516fe81d6715b37bb4e3790fa4d7fb84d8f148dcef60f44d3</originalsourceid><addsrcrecordid>eNqFkUtr3DAUhUVpaKZp_0KYTZee3itZlr0JLSF9QCCBtGshS1cdTceykZzA_PvKTJI-Nl0JdM85V_oOY-cIGwRs3u82Uz7YbaK84VAuodsA1i_YClvFK4VcvGSrIpQVqhZP2eucdwDAsetesVOOIGUr-IrJ2yUmmDkFu7bjMKY-uDAf1iGuB5q3Zpi2NJshRFo7mig6ipbesBNv9pnePp5n7Punq2-XX6rrm89fLz9eV1ZKOVeOCyIkACVl7YhLbDy16BqFsheq72sSqgNvaqd839au9Vi3zpJvwNe1E2fs4pg73fcDlUGck9nrKYXBpIMeTdB_T2LY6h_jgxYgW4VdCWiOATaNOSfyz14EvYDUO_0EUi8gNXS6gCzG8z83P9ueyBXBu0eBydbsfTLRhvxbJ7qmfFcW3Yejjgqnh0BJZxsWhi4ksrN2Y_j_Wy7-ibD7EEPZ-pMOlHfjfYqlBY06cw36bql9aR1L4bJDIX4BOVusBA</addsrcrecordid><sourcetype>Open Access Repository</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype></control><display><type>article</type><title>Psychiatric comorbidity in methamphetamine dependence</title><source>MEDLINE</source><source>Elsevier ScienceDirect Journals</source><creator>Salo, Ruth ; Flower, Keith ; Kielstein, Anousheh ; Leamon, Martin H ; Nordahl, Thomas E ; Galloway, Gantt P</creator><creatorcontrib>Salo, Ruth ; Flower, Keith ; Kielstein, Anousheh ; Leamon, Martin H ; Nordahl, Thomas E ; Galloway, Gantt P</creatorcontrib><description>Abstract The primary aim of the present study was to assess the prevalence of psychiatric comorbidity in a large sample of methamphetamine (MA)-dependent subjects using a validated structured clinical interview, without limitation to sexual orientation or participation in a treatment program. The secondary aim was to assess whether the prevalence of psychiatric comorbidities varied by gender. Structured clinical interviews (SCIDs) were administered to 189 MA-dependent subjects and lifetime prevalence of DSM-IV diagnoses was assessed. Across the sample, 28.6% had primary psychotic disorders, 23.8% of which were substance-induced; 13.2% had MA-induced delusional disorders and 11.1% had MA-induced hallucinations. A substantial number of lifetime mood disorders were identified that were not substance-induced (32.3%), whereas 14.8% had mood disorders induced by substances, and 10.6% had mood disorders induced by amphetamines. Of all participants, 26.5% had anxiety disorders and 3.7% had a substance-induced anxiety disorder, all of which were induced by MA. Male subjects reported a higher percentage of MA-induced delusions compared to female abusers. Given the impact of MA psychosis and other drug-induced symptoms on hospitals and mental health services, the description and characterization of comorbid psychiatric symptoms associated with MA use is of paramount importance.</description><identifier>ISSN: 0165-1781</identifier><identifier>EISSN: 1872-7123</identifier><identifier>DOI: 10.1016/j.psychres.2010.09.014</identifier><identifier>PMID: 21055832</identifier><identifier>CODEN: PSRSDR</identifier><language>eng</language><publisher>Kidlington: Elsevier Ireland Ltd</publisher><subject>Adolescent ; Adult ; Aged ; Amphetamine-Related Disorders - epidemiology ; Biological and medical sciences ; Comorbidity ; Female ; Gender ; Humans ; Male ; Medical sciences ; Mental Disorders - diagnosis ; Mental Disorders - epidemiology ; Middle Aged ; Neuropharmacology ; Pharmacology. Drug treatments ; Psychiatric comorbidity ; Psychiatric Status Rating Scales ; Psychiatry ; Psychoanaleptics: cns stimulant, antidepressant agent, nootropic agent, mood stabilizer ; Psychoanaleptics: cns stimulant, antidepressant agent, nootropic agent, mood stabilizer..., (alzheimer disease) ; Psychology. Psychoanalysis. Psychiatry ; Psychopharmacology ; Severity of Illness Index ; Stimulants ; Substance abuse ; Young Adult</subject><ispartof>Psychiatry research, 2011-04, Vol.186 (2), p.356-361</ispartof><rights>Elsevier Ireland Ltd</rights><rights>2010 Elsevier Ireland Ltd</rights><rights>2015 INIST-CNRS</rights><rights>Copyright © 2010 Elsevier Ireland Ltd. All rights reserved.</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c555t-d23ee1e007554de2516fe81d6715b37bb4e3790fa4d7fb84d8f148dcef60f44d3</citedby><cites>FETCH-LOGICAL-c555t-d23ee1e007554de2516fe81d6715b37bb4e3790fa4d7fb84d8f148dcef60f44d3</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktohtml>$$Uhttps://www.sciencedirect.com/science/article/pii/S0165178110005913$$EHTML$$P50$$Gelsevier$$H</linktohtml><link.rule.ids>230,314,776,780,881,3537,27901,27902,65306</link.rule.ids><backlink>$$Uhttp://pascal-francis.inist.fr/vibad/index.php?action=getRecordDetail&idt=23965165$$DView record in Pascal Francis$$Hfree_for_read</backlink><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/21055832$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Salo, Ruth</creatorcontrib><creatorcontrib>Flower, Keith</creatorcontrib><creatorcontrib>Kielstein, Anousheh</creatorcontrib><creatorcontrib>Leamon, Martin H</creatorcontrib><creatorcontrib>Nordahl, Thomas E</creatorcontrib><creatorcontrib>Galloway, Gantt P</creatorcontrib><title>Psychiatric comorbidity in methamphetamine dependence</title><title>Psychiatry research</title><addtitle>Psychiatry Res</addtitle><description>Abstract The primary aim of the present study was to assess the prevalence of psychiatric comorbidity in a large sample of methamphetamine (MA)-dependent subjects using a validated structured clinical interview, without limitation to sexual orientation or participation in a treatment program. The secondary aim was to assess whether the prevalence of psychiatric comorbidities varied by gender. Structured clinical interviews (SCIDs) were administered to 189 MA-dependent subjects and lifetime prevalence of DSM-IV diagnoses was assessed. Across the sample, 28.6% had primary psychotic disorders, 23.8% of which were substance-induced; 13.2% had MA-induced delusional disorders and 11.1% had MA-induced hallucinations. A substantial number of lifetime mood disorders were identified that were not substance-induced (32.3%), whereas 14.8% had mood disorders induced by substances, and 10.6% had mood disorders induced by amphetamines. Of all participants, 26.5% had anxiety disorders and 3.7% had a substance-induced anxiety disorder, all of which were induced by MA. Male subjects reported a higher percentage of MA-induced delusions compared to female abusers. Given the impact of MA psychosis and other drug-induced symptoms on hospitals and mental health services, the description and characterization of comorbid psychiatric symptoms associated with MA use is of paramount importance.</description><subject>Adolescent</subject><subject>Adult</subject><subject>Aged</subject><subject>Amphetamine-Related Disorders - epidemiology</subject><subject>Biological and medical sciences</subject><subject>Comorbidity</subject><subject>Female</subject><subject>Gender</subject><subject>Humans</subject><subject>Male</subject><subject>Medical sciences</subject><subject>Mental Disorders - diagnosis</subject><subject>Mental Disorders - epidemiology</subject><subject>Middle Aged</subject><subject>Neuropharmacology</subject><subject>Pharmacology. Drug treatments</subject><subject>Psychiatric comorbidity</subject><subject>Psychiatric Status Rating Scales</subject><subject>Psychiatry</subject><subject>Psychoanaleptics: cns stimulant, antidepressant agent, nootropic agent, mood stabilizer</subject><subject>Psychoanaleptics: cns stimulant, antidepressant agent, nootropic agent, mood stabilizer..., (alzheimer disease)</subject><subject>Psychology. Psychoanalysis. Psychiatry</subject><subject>Psychopharmacology</subject><subject>Severity of Illness Index</subject><subject>Stimulants</subject><subject>Substance abuse</subject><subject>Young Adult</subject><issn>0165-1781</issn><issn>1872-7123</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2011</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNqFkUtr3DAUhUVpaKZp_0KYTZee3itZlr0JLSF9QCCBtGshS1cdTceykZzA_PvKTJI-Nl0JdM85V_oOY-cIGwRs3u82Uz7YbaK84VAuodsA1i_YClvFK4VcvGSrIpQVqhZP2eucdwDAsetesVOOIGUr-IrJ2yUmmDkFu7bjMKY-uDAf1iGuB5q3Zpi2NJshRFo7mig6ipbesBNv9pnePp5n7Punq2-XX6rrm89fLz9eV1ZKOVeOCyIkACVl7YhLbDy16BqFsheq72sSqgNvaqd839au9Vi3zpJvwNe1E2fs4pg73fcDlUGck9nrKYXBpIMeTdB_T2LY6h_jgxYgW4VdCWiOATaNOSfyz14EvYDUO_0EUi8gNXS6gCzG8z83P9ueyBXBu0eBydbsfTLRhvxbJ7qmfFcW3Yejjgqnh0BJZxsWhi4ksrN2Y_j_Wy7-ibD7EEPZ-pMOlHfjfYqlBY06cw36bql9aR1L4bJDIX4BOVusBA</recordid><startdate>20110430</startdate><enddate>20110430</enddate><creator>Salo, Ruth</creator><creator>Flower, Keith</creator><creator>Kielstein, Anousheh</creator><creator>Leamon, Martin H</creator><creator>Nordahl, Thomas E</creator><creator>Galloway, Gantt P</creator><general>Elsevier Ireland Ltd</general><general>Elsevier</general><scope>IQODW</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>5PM</scope></search><sort><creationdate>20110430</creationdate><title>Psychiatric comorbidity in methamphetamine dependence</title><author>Salo, Ruth ; Flower, Keith ; Kielstein, Anousheh ; Leamon, Martin H ; Nordahl, Thomas E ; Galloway, Gantt P</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c555t-d23ee1e007554de2516fe81d6715b37bb4e3790fa4d7fb84d8f148dcef60f44d3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2011</creationdate><topic>Adolescent</topic><topic>Adult</topic><topic>Aged</topic><topic>Amphetamine-Related Disorders - epidemiology</topic><topic>Biological and medical sciences</topic><topic>Comorbidity</topic><topic>Female</topic><topic>Gender</topic><topic>Humans</topic><topic>Male</topic><topic>Medical sciences</topic><topic>Mental Disorders - diagnosis</topic><topic>Mental Disorders - epidemiology</topic><topic>Middle Aged</topic><topic>Neuropharmacology</topic><topic>Pharmacology. Drug treatments</topic><topic>Psychiatric comorbidity</topic><topic>Psychiatric Status Rating Scales</topic><topic>Psychiatry</topic><topic>Psychoanaleptics: cns stimulant, antidepressant agent, nootropic agent, mood stabilizer</topic><topic>Psychoanaleptics: cns stimulant, antidepressant agent, nootropic agent, mood stabilizer..., (alzheimer disease)</topic><topic>Psychology. Psychoanalysis. Psychiatry</topic><topic>Psychopharmacology</topic><topic>Severity of Illness Index</topic><topic>Stimulants</topic><topic>Substance abuse</topic><topic>Young Adult</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Salo, Ruth</creatorcontrib><creatorcontrib>Flower, Keith</creatorcontrib><creatorcontrib>Kielstein, Anousheh</creatorcontrib><creatorcontrib>Leamon, Martin H</creatorcontrib><creatorcontrib>Nordahl, Thomas E</creatorcontrib><creatorcontrib>Galloway, Gantt P</creatorcontrib><collection>Pascal-Francis</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>PubMed Central (Full Participant titles)</collection><jtitle>Psychiatry research</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Salo, Ruth</au><au>Flower, Keith</au><au>Kielstein, Anousheh</au><au>Leamon, Martin H</au><au>Nordahl, Thomas E</au><au>Galloway, Gantt P</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Psychiatric comorbidity in methamphetamine dependence</atitle><jtitle>Psychiatry research</jtitle><addtitle>Psychiatry Res</addtitle><date>2011-04-30</date><risdate>2011</risdate><volume>186</volume><issue>2</issue><spage>356</spage><epage>361</epage><pages>356-361</pages><issn>0165-1781</issn><eissn>1872-7123</eissn><coden>PSRSDR</coden><abstract>Abstract The primary aim of the present study was to assess the prevalence of psychiatric comorbidity in a large sample of methamphetamine (MA)-dependent subjects using a validated structured clinical interview, without limitation to sexual orientation or participation in a treatment program. The secondary aim was to assess whether the prevalence of psychiatric comorbidities varied by gender. Structured clinical interviews (SCIDs) were administered to 189 MA-dependent subjects and lifetime prevalence of DSM-IV diagnoses was assessed. Across the sample, 28.6% had primary psychotic disorders, 23.8% of which were substance-induced; 13.2% had MA-induced delusional disorders and 11.1% had MA-induced hallucinations. A substantial number of lifetime mood disorders were identified that were not substance-induced (32.3%), whereas 14.8% had mood disorders induced by substances, and 10.6% had mood disorders induced by amphetamines. Of all participants, 26.5% had anxiety disorders and 3.7% had a substance-induced anxiety disorder, all of which were induced by MA. Male subjects reported a higher percentage of MA-induced delusions compared to female abusers. Given the impact of MA psychosis and other drug-induced symptoms on hospitals and mental health services, the description and characterization of comorbid psychiatric symptoms associated with MA use is of paramount importance.</abstract><cop>Kidlington</cop><pub>Elsevier Ireland Ltd</pub><pmid>21055832</pmid><doi>10.1016/j.psychres.2010.09.014</doi><tpages>6</tpages><oa>free_for_read</oa></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 0165-1781 |
| ispartof | Psychiatry research, 2011-04, Vol.186 (2), p.356-361 |
| issn | 0165-1781 1872-7123 |
| language | eng |
| recordid | cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_3058719 |
| source | MEDLINE; Elsevier ScienceDirect Journals |
| subjects | Adolescent Adult Aged Amphetamine-Related Disorders - epidemiology Biological and medical sciences Comorbidity Female Gender Humans Male Medical sciences Mental Disorders - diagnosis Mental Disorders - epidemiology Middle Aged Neuropharmacology Pharmacology. Drug treatments Psychiatric comorbidity Psychiatric Status Rating Scales Psychiatry Psychoanaleptics: cns stimulant, antidepressant agent, nootropic agent, mood stabilizer Psychoanaleptics: cns stimulant, antidepressant agent, nootropic agent, mood stabilizer..., (alzheimer disease) Psychology. Psychoanalysis. Psychiatry Psychopharmacology Severity of Illness Index Stimulants Substance abuse Young Adult |
| title | Psychiatric comorbidity in methamphetamine dependence |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-02-01T17%3A22%3A59IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-elsevier_pubme&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Psychiatric%20comorbidity%20in%20methamphetamine%20dependence&rft.jtitle=Psychiatry%20research&rft.au=Salo,%20Ruth&rft.date=2011-04-30&rft.volume=186&rft.issue=2&rft.spage=356&rft.epage=361&rft.pages=356-361&rft.issn=0165-1781&rft.eissn=1872-7123&rft.coden=PSRSDR&rft_id=info:doi/10.1016/j.psychres.2010.09.014&rft_dat=%3Celsevier_pubme%3E1_s2_0_S0165178110005913%3C/elsevier_pubme%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_id=info:pmid/21055832&rft_els_id=1_s2_0_S0165178110005913&rfr_iscdi=true |